Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dyne Therapeutics, Inc. (DYN : NSDQ)

• Company Description    Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 191

• Price / Volume Information    Yesterday's Closing Price: $13.18 Daily Weekly Monthly 20 Day Moving Average: 2,196,233 shares Shares Outstanding: 142.26 (millions) Market Capitalization: $1,874.32 (millions) Beta: 1.10 52 Week High: $37.08 52 Week Low: $6.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.40% 3.50% 12 Week 22.22% 10.96% Year To Date -44.08% -50.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1560 TRAPELO ROAD - WALTHAM,MA 02451 USA ph: 781-786-8230 fax: 781-786-8866 ir@dyne-tx.com http://www.dyne-tx.com

• General Corporate Information    Officers John G. Cox - President; Chief Executive Officer and Director Jason Rhodes - Director and Chairman of the Board Richard Scalzo - Senior Vice President; Head of Finance and Adminis Ed Hurwitz - Director Carlo Incerti - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 26818M108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 142.26 Most Recent Split Date: (:1) Beta: 1.10 Market Capitalization: $1,874.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -38.57% vs. Previous Quarter: 7.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -64.12 03/31/25 - -52.83 12/31/24 - -49.05 ROA 06/30/25 - -56.75 03/31/25 - -48.84 12/31/24 - -45.21 Current Ratio 06/30/25 - 16.83 03/31/25 - 20.35 12/31/24 - 15.60 Quick Ratio 06/30/25 - 16.83 03/31/25 - 20.35 12/31/24 - 15.60 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 4.02 03/31/25 - 5.89 12/31/24 - 6.19 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.17 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 14.74 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©